NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free BIOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,600 shsAverage Volume122,781 shsMarket Capitalization$209.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BioPlus Acquisition alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About BioPlus Acquisition Stock (NASDAQ:BIOS)BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. BIOS Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comImugene and Kincell Bio Announce Strategic Manufacturing and Process Development PartnershipApril 3, 2024 | benzinga.comLouis G Lange's Net WorthMay 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 9, 2024 | msn.comWhy Intelligent Bio Solutions Stock Is Ripping HigherJanuary 22, 2024 | investing.comBioPlus Co Ltd (099430)October 4, 2023 | msn.comSPAC BioPlus, Avertix terminate merger; BioPlus to liquidateOctober 4, 2023 | markets.businessinsider.comAvertix, BIOS Acquisition Agree To Terminate Merger DealOctober 4, 2023 | finance.yahoo.comAvertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business CombinationMay 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)October 4, 2023 | finance.yahoo.comBioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to LiquidateAugust 16, 2023 | finance.yahoo.comHeart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringAugust 16, 2023 | finance.yahoo.comAvertix Partners with Institute on Implantable Heart Attack Detection SystemJuly 20, 2023 | finance.yahoo.comAvertix Medical Welcomes Renown Cardiologist to Board of DirectorsJuly 17, 2023 | finance.yahoo.comRenown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of DirectorsJune 13, 2023 | finance.yahoo.comAvertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth OrlandoMay 26, 2023 | seekingalpha.comBIOS BioPlus Acquisition Corp.May 5, 2023 | msn.comSPAC BIOS to merge with cardiac device maker AvertixMay 3, 2023 | finance.yahoo.comAvertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition CorporationMarch 18, 2023 | money.usnews.comBioPlus Acquisition Corp - Ordinary Shares - Class ASeptember 23, 2022 | wsj.comBioPlus Acquisition Corp. Cl ASeptember 20, 2022 | finance.yahoo.comBioPlus Acquisition Corp. (BIOS)September 3, 2022 | investing.comBioPlus Acquisition Corp (BIOS)August 13, 2022 | reuters.comBioPlus Acquisition CorpAugust 10, 2022 | finance.yahoo.comWhat Type Of Shareholders Own The Most Number of BioPlus Acquisition Corp. (NASDAQ:BIOS) Shares?See More Headlines Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CUSIPN/A CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.20 million OptionableNot Optionable Beta0.01 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jonathan M. N. Rigby MBA (Age 55)Chairman & Chief Bus. Officer Mr. R. Ross Haghighat (Age 59)CEO, CFO & Director Key CompetitorsHelix Acquisition Corp. IINASDAQ:HLXBRCF AcquisitionNYSE:RCFAKeen Vision AcquisitionNASDAQ:KVACGores Holdings IXNASDAQ:GHIXSDCL EDGE AcquisitionNYSE:SEDAView All Competitors BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an initial public offering (IPO) on Friday, December 3rd 2021. The company issued 18,000,000 shares at $10.00 per share. Cantor acted as the underwriter for the IPO. This page (NASDAQ:BIOS) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsWarren Buffet Stockpiling Gold?Reagan Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
